This article contains links to products or services from one or more of our advertisers or partners. We may receive a commission when you click or make a purchase using our site. Learn more about how we make money.

How to buy Zymeworks stock | $41.61

Own Zymeworks stock in just a few minutes.

Posted

Fact checked

Zymeworks Inc is a biotechnology business based in the US. Zymeworks shares (ZYME) are listed on the NYSE and all prices are listed in US Dollars. Zymeworks employs 325 staff and has a trailing 12-month revenue of around USD$25.1 million.

How to buy shares in Zymeworks

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Zymeworks. Find the stock by name or ticker symbol: ZYME. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Zymeworks reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$41.61, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Zymeworks, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Zymeworks. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Zymeworks share price

Use our graph to track the performance of ZYME stocks over time.

Zymeworks shares at a glance

Information last updated 2020-11-30.
Latest market close USD$41.61
52-week range USD$20.33 - USD$53.15
50-day moving average USD$43.0238
200-day moving average USD$37.6888
Wall St. target price USD$24.88
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-1.63

Buy Zymeworks shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Zymeworks stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Zymeworks price performance over time

Historical closes compared with the close of $41.61 from 2020-11-16

1 week (2020-11-25) -14.29%
1 month (2020-11-06) 0.14%
3 months (2020-09-04) 31.26%
6 months (2020-06-05) 13.69%
1 year (2019-12-05) -0.74%
2 years (2018-12-04) 224.82%
3 years (2017-12-05) 390.82%
5 years (2015-12-02) N/A

Zymeworks financials

Revenue TTM USD$25.1 million
Gross profit TTM USD$-86,356,000
Return on assets TTM -28.78%
Return on equity TTM -57.94%
Profit margin 0%
Book value $9.44
Market capitalisation USD$2.4 billion

TTM: trailing 12 months

Shorting Zymeworks shares

There are currently 1.3 million Zymeworks shares held short by investors – that's known as Zymeworks's "short interest". This figure is 29.9% down from 1.9 million last month.

There are a few different ways that this level of interest in shorting Zymeworks shares can be evaluated.

Zymeworks's "short interest ratio" (SIR)

Zymeworks's "short interest ratio" (SIR) is the quantity of Zymeworks shares currently shorted divided by the average quantity of Zymeworks shares traded daily (recently around 269386.96537678). Zymeworks's SIR currently stands at 4.91. In other words for every 100,000 Zymeworks shares traded daily on the market, roughly 4910 shares are currently held short.

However Zymeworks's short interest can also be evaluated against the total number of Zymeworks shares, or, against the total number of tradable Zymeworks shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Zymeworks's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Zymeworks shares in existence, roughly 30 shares are currently held short) or 0.0291% of the tradable shares (for every 100,000 tradable Zymeworks shares, roughly 29 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Zymeworks.

Find out more about how you can short Zymeworks stock.

Zymeworks share dividends

We're not expecting Zymeworks to pay a dividend over the next 12 months.

Zymeworks share price volatility

Over the last 12 months, Zymeworks's shares have ranged in value from as little as $20.33 up to $53.15. A popular way to gauge a stock's volatility is its "beta".

ZYME.US volatility(beta: 0.82)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Zymeworks's is 0.8202. This would suggest that Zymeworks's shares are less volatile than average (for this exchange).

Zymeworks overview

Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I and Phase II clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and other tumors; and ZW49, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced or metastatic HER2-expressing cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; collaboration with Applied BioMath, LLC.; and a research collaboration with ImmunoPrecise Antibodies Ltd. for the development of multiple antibody candidates to fight COVID-19. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site